Immutrin Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $87M

  • Investors
  • 9

Immutrin General Information

Description

Developer of antibody-based therapies intended to treat amyloidosis by removing systemic amyloid deposits. The company offers targeted antibodies with selective fibril-binding mechanisms, enabling researchers and healthcare providers to address amyloid-related diseases and improve disease management.

Contact Information

Website
www.immutrin.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Cambridge Innovation Capital
  • 22 Station Road
  • Cambridge CB1 2JD
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Cambridge Innovation Capital
  • 22 Station Road
  • Cambridge CB1 2JD
  • England, United Kingdom

Immutrin Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immutrin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A) 24-Mar-2026 $87M Completed Pre-Clinical Trials
5. Seed Round 25-Sep-2024 Completed Pre-Clinical Trials
4. Seed Round 04-Apr-2023 Completed Pre-Clinical Trials
3. Seed Round 31-Mar-2022 Completed Pre-Clinical Trials
2. Seed Round 02-Dec-2019 $387K $387K Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Product Development
To view Immutrin’s complete valuation and funding history, request access »

Immutrin Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series Seed-4
Series Seed-3
Series Seed-2 15,000 $0.001318 $26.36 $26.36 1x $26.36 6.34%
Series Seed-1 30,000 $0.001318 $13.18 $13.18 1x $13.18 12.67%
To view Immutrin’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Immutrin Patents

  • 9

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

Immutrin Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202418667-D0 Anti-fibril antibodies with engineered fc regions Pending 19-Dec-2024
WO-2026132571-A1 Anti-fibril antibodies with engineered fc regions Pending 19-Dec-2024
WO-2026132571-A9 Anti-fibril antibodies with engineered fc regions Pending 19-Dec-2024
AU-2024304161-A1 Anti-fibril antibodies Pending 14-Jun-2023
EP-4727650-A1 Anti-fibril antibodies Pending 14-Jun-2023 C07K16/18
To view Immutrin’s complete patent history, request access »

Immutrin Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immutrin Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cambridge Enterprise Ventures Venture Capital Minority
F-Prime Venture Capital Minority
Frazier Healthcare Partners PE/Buyout Minority
Qiming Venture Partners Venture Capital Minority
SR One Corporate Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Immutrin FAQs

  • When was Immutrin founded?

    Immutrin was founded in 2019.

  • Where is Immutrin headquartered?

    Immutrin is headquartered in Cambridge, United Kingdom.

  • What is the size of Immutrin?

    Immutrin has 8 total employees.

  • What industry is Immutrin in?

    Immutrin’s primary industry is Drug Discovery.

  • Is Immutrin a private or public company?

    Immutrin is a Private company.

  • What is Immutrin’s current revenue?

    The current revenue for Immutrin is .

  • How much funding has Immutrin raised over time?

    Immutrin has raised $91.8M.

  • Who are Immutrin’s investors?

    Cambridge Enterprise Ventures, F-Prime, Frazier Healthcare Partners, Qiming Venture Partners, and SR One are 5 of 9 investors who have invested in Immutrin.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process